ZIAC Drug Patent Profile

When do Ziac patents expire, and when can generic versions of Ziac launch?

Ziac is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in ZIAC is bisoprolol fumarate; hydrochlorothiazide. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ziac

A generic version of ZIAC was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25^th, 2000.

Summary for ZIAC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	131
Drug Prices:	Drug price information for ZIAC
What excipients (inactive ingredients) are in ZIAC?	ZIAC excipients list
DailyMed Link:	ZIAC at DailyMed

See drug prices for ZIAC

Pharmacology for ZIAC

Drug Class	Thiazide Diuretic beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for ZIAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-003	Mar 26, 1993	AB	RX	Yes	No
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-001	Mar 26, 1993	AB	RX	Yes	No
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-002	Mar 26, 1993	AB	RX	Yes	Yes

Expired US Patents for ZIAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-003	Mar 26, 1993	4,258,062
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-002	Mar 26, 1993	4,258,062*PED
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-001	Mar 26, 1993	4,258,062*PED
Teva Branded Pharm	ZIAC	bisoprolol fumarate; hydrochlorothiazide	TABLET;ORAL	020186-003	Mar 26, 1993	4,358,062*PED

International Patents for ZIAC

See the table below for patents covering ZIAC around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	177868	PROCESS FOR PREPARING PHENOXY-AMINO-PROPANOLS
Hong Kong	39483	PHENOXY-AMINO-PROPANOLS AND PROCESSES FOR THEIR PREPARATION
Australia	520307
Netherlands	185665

ZIAC Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for ZIAC

Introduction

ZIAC, a combination drug consisting of bisoprolol fumarate and hydrochlorothiazide, is widely used for the treatment of hypertension. To understand its market dynamics and financial trajectory, it is crucial to delve into various aspects including its indications, market segmentation, pricing, and the broader pharmaceutical industry context.

Indications and Usage

ZIAC is indicated for the management of hypertension, combining a beta1-selective adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide) in a once-daily dosage. This combination enhances the antihypertensive effect, providing significant blood pressure reductions compared to either component used alone[2][4].

Market Segmentation

The market for antihypertensive drugs, including ZIAC, is segmented based on drug classes. ZIAC falls under the category of beta blockers and diuretics. The global chronic heart failure drugs market, which also includes hypertension treatments, is segmented into various drug classes such as ACE inhibitors, ARBs, beta blockers, and diuretics among others[1].

Competitive Landscape

The antihypertensive drug market is highly competitive, with several major players including Amgen, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, and others. These companies have a diverse portfolio of drugs and significant financial resources to invest in research and development, marketing, and distribution[1].

Pricing and Cost

The cost of ZIAC can vary depending on the pharmacy and location. For instance, a supply of 30 tablets of ZIAC (10 mg-6.25 mg) can cost around $294[5]. The pricing of ZIAC, like other pharmaceuticals, is influenced by factors such as research and development costs, production expenses, regulatory approvals, and market demand.

Financial Trajectory

Revenue Generation

The revenue generated by ZIAC contributes to the overall financial health of its manufacturing company. The profits from best-selling drugs like ZIAC are crucial for reinvesting in research and development for the next generation of drugs. This cycle is essential for pharmaceutical companies to maintain their competitive edge and continue innovating[3].

Impact of Drug Prices on Research

The financial trajectory of ZIAC and similar drugs is closely tied to the broader discussion on drug prices and their impact on research. Academic studies have shown that reducing current drug revenues can lead to a decrease in future research and the number of new drug discoveries. This is because a significant portion of the profits from successful drugs is used to cover the costs of failed research efforts, long delays between initial research and product sales, and new research initiatives[3].

Market Trends and Forecast

The global chronic heart failure drugs market, which includes antihypertensive medications like ZIAC, is expected to grow over the forecast period from 2024 to 2031. This growth is driven by increasing prevalence of cardiovascular diseases, aging populations, and advancements in medical treatments. The market attractiveness analysis and market profitability analysis by key products and regions indicate a favorable outlook for drugs like ZIAC[1].

Regulatory and Market Challenges

Regulatory Environment

The regulatory environment plays a critical role in the financial trajectory of ZIAC. FDA approvals, labeling requirements, and post-marketing surveillance are essential for maintaining the drug's market presence. Any changes in regulatory policies or safety concerns can significantly impact the drug's sales and profitability[2][4].

Market Competition and Pricing Pressures

The antihypertensive drug market is subject to intense competition, which can lead to pricing pressures. Generic versions of drugs and new innovative treatments can erode the market share of established drugs like ZIAC. Additionally, government price controls and other measures to reduce drug prices can affect the revenue and profitability of pharmaceutical companies[3].

Patient Assistance and Access

To improve patient access, various patient assistance programs and copay cards are available for ZIAC. These initiatives help reduce the financial burden on patients, thereby increasing the drug's market penetration and overall sales[5].

Conclusion

The market dynamics and financial trajectory of ZIAC are influenced by a complex interplay of factors including its indications, market segmentation, pricing, competitive landscape, and regulatory environment. As the global chronic heart failure drugs market continues to grow, the financial health of ZIAC will depend on its ability to maintain market share, adapt to regulatory changes, and contribute to the ongoing research and development efforts of its manufacturing company.

Key Takeaways

• Indications and Usage: ZIAC is used for the treatment of hypertension, combining bisoprolol fumarate and hydrochlorothiazide.
• Market Segmentation: Part of the broader antihypertensive drug market, segmented by drug classes.
• Pricing and Cost: Costs around $294 for a 30-tablet supply, varying by pharmacy and location.
• Financial Trajectory: Profits from ZIAC are crucial for reinvesting in research and development.
• Regulatory and Market Challenges: Subject to FDA regulations, market competition, and pricing pressures.
• Patient Assistance: Various programs available to improve patient access.

FAQs

What is ZIAC used for?

ZIAC is indicated for the management of hypertension, combining a beta1-selective adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide).

How much does ZIAC cost?

The cost of ZIAC can vary, but a supply of 30 tablets (10 mg-6.25 mg) can cost around $294 depending on the pharmacy.

What are the key components of ZIAC?

ZIAC combines bisoprolol fumarate, a beta1-selective adrenoceptor blocking agent, and hydrochlorothiazide, a benzothiadiazine diuretic.

How does ZIAC impact the financial health of its manufacturing company?

The profits from ZIAC are crucial for reinvesting in research and development for the next generation of drugs, contributing to the company's financial health and competitive edge.

What are the potential challenges for ZIAC in the market?

ZIAC faces challenges from market competition, regulatory changes, pricing pressures, and the availability of generic or innovative treatments.

Sources

1. Chronic Heart Failure Drugs Market and Forecast 2024-2031 - iHealthcareAnalyst
2. ZIAC® (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets Rx only - FDA
3. The Link Between Drug Prices and Research on the Next Generation of Cures - ITIF
4. ZIAC (Bisoprolol Fumarate and Hydrochlorothiazide) Tablets Rx only Revised March 2011 - FDA
5. Ziac Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com